Dynamic testing of stimulative and suppressive biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients.

CONCLUSION: Our work indicates that by testing biomarkers on patients' PBMCs at an early stage of treatment, the immunotherapeutic effect can be predicted, thus improving patient outcomes and cost efficiency. PMID: 30021101 [PubMed - in process]
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research